The ABPI represents UK-based pharma companies researching the newest and most innovative medicines. Our members make both originator biological medicines and make biosimilar medicines so, for want of a better word, we have a foot in both camps.
Genomics is already delivering precision treatments to patients with remarkable speed: the landscape of life sciences is changing and it’s being driven by information.
Have you ever wondered if the scientists you see in movies that are racing against the clock to prevent a deadly disease breakout actually exist?
“I won’t rest until we manage to deliver solutions that make blood cancer a manageable or even curable condition.” - Dr Catherine Taylor, Therapy Area Lead; Haemotology; Janssen Oncology; Europe, Middle East, Africa.
With over 7,000 new medicines in development, we won't rest until everyone affected by disease can look forward to a brighter tomorrow.
In June 2017, the European Federation of Pharmaceutical Industries and Associations (EFPIA) with support from the ABPI in the UK, launched #WeWontRest.